La gestion des complications nécessite un suivi médical étroit et des ajustements de traitement.
GestionSuivi médicalComplications
Facteurs de risque
5
#1
Quels sont les facteurs de risque connus ?
Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections.
Facteurs de risqueAntécédents familiauxTabagisme
#2
Le tabagisme augmente-t-il le risque ?
Oui, le tabagisme est un facteur de risque significatif pour cette maladie.
TabagismeFacteurs de risqueGranulomatose avec polyangéite
#3
Les infections peuvent-elles déclencher la maladie ?
Certaines infections, comme celles des voies respiratoires, peuvent être des déclencheurs.
InfectionsDéclencheursGranulomatose avec polyangéite
#4
Y a-t-il un lien avec d'autres maladies auto-immunes ?
Oui, les personnes atteintes d'autres maladies auto-immunes peuvent avoir un risque accru.
Maladies auto-immunesFacteurs de risqueGranulomatose avec polyangéite
#5
L'âge influence-t-il le risque ?
La maladie est plus fréquente chez les adultes jeunes à moyens, généralement entre 30 et 60 ans.
ÂgeFacteurs de risqueGranulomatose avec polyangéite
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Granulomatose avec polyangéite : Questions médicales les plus fréquentes",
"headline": "Granulomatose avec polyangéite : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Granulomatose avec polyangéite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-23",
"dateModified": "2025-02-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Granulomatose avec polyangéite"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"url": "https://questionsmedicales.fr/mesh/D056648",
"about": {
"@type": "MedicalCondition",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"code": {
"@type": "MedicalCode",
"code": "D056648",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.111.193"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Granulomatose avec polyangéite",
"alternateName": "Granulomatosis with Polyangiitis",
"code": {
"@type": "MedicalCode",
"code": "D014890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Benjamin Terrier",
"url": "https://questionsmedicales.fr/author/Benjamin%20Terrier",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France benjamin.terrier@aphp.fr."
}
},
{
"@type": "Person",
"name": "Xavier Puéchal",
"url": "https://questionsmedicales.fr/author/Xavier%20Pu%C3%A9chal",
"affiliation": {
"@type": "Organization",
"name": "Centre de Référence des Maladies Systémiques Auto-immunes rares, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. Electronic address: xavier.puechal@aphp.fr."
}
},
{
"@type": "Person",
"name": "Christian Pagnoux",
"url": "https://questionsmedicales.fr/author/Christian%20Pagnoux",
"affiliation": {
"@type": "Organization",
"name": "Vasculitis Clinic, Division of Rheumatology, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada."
}
},
{
"@type": "Person",
"name": "Roman Yatsyshyn",
"url": "https://questionsmedicales.fr/author/Roman%20Yatsyshyn",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine #1, Clinical Immunology and Allergology Named After Academician Ye. M. Neiko, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk, 76000, Ukraine."
}
},
{
"@type": "Person",
"name": "Olena Zimba",
"url": "https://questionsmedicales.fr/author/Olena%20Zimba",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Modeling Low Muscle Mass Screening in Hemodialysis Patients.",
"datePublished": "2022-10-21",
"url": "https://questionsmedicales.fr/article/36273447",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000526866"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fat-Free Mass Index as a Surrogate Marker of Appendicular Skeletal Muscle Mass Index for Low Muscle Mass Screening in Sarcopenia.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36179769",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jamda.2022.08.016"
}
},
{
"@type": "ScholarlyArticle",
"name": "The dilemma of recalling well-circumscribed masses in a screening population: A narrative literature review and exploration of Dutch screening practice.",
"datePublished": "2023-05-03",
"url": "https://questionsmedicales.fr/article/37169601",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.breast.2023.05.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology.",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35971172",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-022-08394-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "The efficacy of mass screening for chronic obstructive pulmonary disease using screening questionnaires in a medical health check-up population.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36057534",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.resinv.2022.07.005"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies auto-immunes",
"item": "https://questionsmedicales.fr/mesh/D001327"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"item": "https://questionsmedicales.fr/mesh/D056648"
},
{
"@type": "ListItem",
"position": 5,
"name": "Granulomatose avec polyangéite",
"item": "https://questionsmedicales.fr/mesh/D014890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Granulomatose avec polyangéite - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Granulomatose avec polyangéite",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Granulomatose avec polyangéite",
"description": "Comment diagnostiquer la granulomatose avec polyangéite ?\nQuels tests sanguins sont utilisés pour le diagnostic ?\nQuel rôle joue la biopsie dans le diagnostic ?\nQuels symptômes cliniques orientent vers cette maladie ?\nComment les examens d'imagerie aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Mass+Screening#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Granulomatose avec polyangéite",
"description": "Quels sont les symptômes courants de cette maladie ?\nLa granulomatose affecte-t-elle les voies respiratoires ?\nQuels problèmes rénaux peuvent survenir ?\nY a-t-il des manifestations cutanées ?\nLes symptômes varient-ils d'un patient à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Mass+Screening#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Granulomatose avec polyangéite",
"description": "Peut-on prévenir la granulomatose avec polyangéite ?\nComment éviter les complications ?\nLes vaccinations sont-elles recommandées ?\nY a-t-il des conseils de mode de vie à suivre ?\nLes patients doivent-ils éviter certains médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Mass+Screening#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Granulomatose avec polyangéite",
"description": "Quels traitements sont utilisés pour cette maladie ?\nComment les corticostéroïdes aident-ils ?\nQuels sont les effets secondaires des traitements ?\nLa thérapie biologique est-elle une option ?\nQuelle est l'importance du suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Mass+Screening#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Granulomatose avec polyangéite",
"description": "Quelles sont les complications possibles ?\nComment l'insuffisance rénale se manifeste-t-elle ?\nLes infections sont-elles fréquentes ?\nQuels problèmes pulmonaires peuvent survenir ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Mass+Screening#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Granulomatose avec polyangéite",
"description": "Quels sont les facteurs de risque connus ?\nLe tabagisme augmente-t-il le risque ?\nLes infections peuvent-elles déclencher la maladie ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nL'âge influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Mass+Screening#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la granulomatose avec polyangéite ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, des biopsies et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps anti-PR3 et des marqueurs d'inflammation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet d'identifier les granulomes et l'inflammation des vaisseaux."
}
},
{
"@type": "Question",
"name": "Quels symptômes cliniques orientent vers cette maladie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs articulaires, des éruptions cutanées et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Comment les examens d'imagerie aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les examens comme la radiographie ou l'IRM montrent des anomalies dans les poumons et les reins."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de cette maladie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, perte de poids, et douleurs musculaires."
}
},
{
"@type": "Question",
"name": "La granulomatose affecte-t-elle les voies respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des sinusites, des saignements de nez et des toux persistantes."
}
},
{
"@type": "Question",
"name": "Quels problèmes rénaux peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des atteintes rénales peuvent entraîner une insuffisance rénale et des urines anormales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des manifestations cutanées ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées, des nodules et des ulcères peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'un patient à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la granulomatose avec polyangéite ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical peut aider."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce et un suivi régulier permettent de réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent être recommandées pour prévenir certaines infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils de mode de vie à suivre ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est conseillé."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains médicaments ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aggraver la maladie et doivent être évités."
}
},
{
"@type": "Question",
"name": "Quels traitements sont utilisés pour cette maladie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs pour réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les corticostéroïdes aident-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils réduisent l'inflammation et soulagent les symptômes rapidement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des infections, des troubles digestifs et des problèmes osseux."
}
},
{
"@type": "Question",
"name": "La thérapie biologique est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des thérapies biologiques ciblées peuvent être utilisées pour les cas réfractaires."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier est crucial pour ajuster le traitement et surveiller les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance rénale, les infections et les problèmes pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment l'insuffisance rénale se manifeste-t-elle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par une diminution de la production d'urine et un gonflement."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients sont plus susceptibles de développer des infections en raison du traitement."
}
},
{
"@type": "Question",
"name": "Quels problèmes pulmonaires peuvent survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications pulmonaires peuvent inclure des hémorragies et des nodules pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical étroit et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque significatif pour cette maladie."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles déclencher la maladie ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme celles des voies respiratoires, peuvent être des déclencheurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La maladie est plus fréquente chez les adultes jeunes à moyens, généralement entre 30 et 60 ans."
}
}
]
}
]
}
Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France benjamin.terrier@aphp.fr.
Université Paris Cité, Paris, France.
Publications dans "Granulomatose avec polyangéite" :
Centre de Référence des Maladies Systémiques Auto-immunes rares, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. Electronic address: xavier.puechal@aphp.fr.
Publications dans "Granulomatose avec polyangéite" :
Department of Internal Medicine #1, Clinical Immunology and Allergology Named After Academician Ye. M. Neiko, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk, 76000, Ukraine.
Publications dans "Granulomatose avec polyangéite" :
Department of Internal Medicine #1, Clinical Immunology and Allergology Named After Academician Ye. M. Neiko, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk, 76000, Ukraine. Doskaliuk_Bo@ifnmu.edu.ua.
Publications dans "Granulomatose avec polyangéite" :
Vaskulitiszentrum Süd, Klinik für Innere Medizin, Rheumatologie und Immunologie, Medius Kliniken - Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Deutschland.
Publications dans "Granulomatose avec polyangéite" :
Computed tomography (CT) can accurately measure muscle mass, which is necessary for diagnosing sarcopenia, even in dialysis patients. However, CT-based screening for such patients is challenging, espe...
Hemodialysis patients (n = 619) who had undergone abdominal CT screening were divided into the development (n = 441) and validation (n = 178) groups. PMI was manually measured using abdominal CT image...
Of all subjects, 226 (37%) were diagnosed with low muscle mass using PMI. A predictive model for low muscle mass was calculated using ten variables: each grip strength, sex, height, dry weight, primar...
Our results facilitate skeletal muscle screening in hemodialysis patients, assisting in sarcopenia prophylaxis and intervention decisions....
We aimed to examine the relationship between the fat-free mass index (FFMI; FFM/height...
Cross-sectional study....
This study included 1313 adults (women, 33.6%) aged 40-87 years (mean age, 55 ± 10 years) from the WASEDA'S Health Study....
Body composition was measured using multifrequency BIA and DXA. Low muscle mass was defined according to the criteria of the Asian Working Group for Sarcopenia 2019....
BIA-measured FFMI showed strong positive correlations with both BIA- (r = 0.96) and DXA-measured (r = 0.95) ASMIs. Similarly, in the subgroup analysis according to age and obesity, the FFMI was correl...
The FFMI showed a strong positive correlation with BIA- and DXA-measured ASMIs, regardless of age and obesity. The FFMI could be a useful simple surrogate marker of the ASMI for low muscle mass screen...
In Dutch breast cancer screening, solitary, new or growing well-circumscribed masses should be recalled for further assessment. This results in cancers detected but also in false positive recalls, esp...
A systematic literature search was performed using PubMed. In addition, follow-up data were retrieved on all 8860 recalled women in a Dutch screening region from 2014 to 2019....
Based on 15 articles identified in the literature search, we found that probably benign well-circumscribed masses that were kept under surveillance had a positive predictive value (PPV) of 0-2%. New o...
To recognize malignancies presenting as well-circumscribed masses, identifying solitary, new or growing lesions is key. This information is missing at initial screening since prior examinations are no...
Newborn screening (NBS) can prevent inborn errors of metabolism (IEMs), which may cause long-term disability and even death in newborns. However, in China, tandem mass spectrometry (MS/MS) screening h...
A Markov model was built to estimate the cost and quality-adjusted life-years (QALYs) of different screening programs. We compared PKU screening using traditional immunofluorescence (IF) with the othe...
The incremental cost-effectiveness ratio (ICER) of detecting all 12 IEMs in the national program is 277,823 RMB per QALY, below three times per capita GDP in Shenzhen. MS/MS screening in Shenzhen can ...
We conclude that the newborn screening using MS/MS in Shenzhen is cost-effective, and the budget affordable for the Shenzhen government. Two concepts for selecting the IEMs to be detected are also pre...
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease, highlighting the need for efficient screening strategies to identify patients with COPD. However, there is little e...
In this cross-sectional study, we originally investigated the efficacy of mass screening for COPD among community residents in the aforementioned region using two COPD screening questionnaires....
From July 2018 through January 2019, 688 participants were enrolled. COPD was diagnosed using the Global Initiative for the Chronic Obstructive Lung Disease criteria. Twenty-one patients were newly di...
Mass screening for COPD using screening questionnaires, particularly the COPD-PS questionnaire, might be useful to identify the early stages of COPD in a medical health check-up population....
Although the study design for identifying specific disease associations using a health insurance database has been well-established, few studies explore unknown comorbidities. We conducted a series of...
Gastric cancer is an inflammation-related cancer triggered by Helicobacter pylori infection. Understanding of the natural disease course has prompted the hypothesis that gastric cancer can be prevente...
The early detection of symptoms and rapid testing are the basis of an efficient screening strategy to control COVID-19 transmission. The olfactory dysfunction is one of the most prevalent symptom and ...
The main goal of this study was to examine the relationship between exposure to mass media health campaign massages and the uptake of non-communicable diseases (NCDs) screening services in Ghana and w...
Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of...
From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso. Individuals of all ages and genders who consented to participate were screened for viral ma...
A total of 15,650 participants were enrolled in the study. Of these, 51.4% were women and the age range was from 1 to 97 years. All participants were screened for HBsAg and 7,507 were also screened fo...
The prevalence of HBV and HCV infections remains high in Burkina Faso. Prevention strategies, including initial mass screening with rapid diagnostic tests and vaccination, need to be intensified....